Disclosures for "Treatment with UX111 Gene Therapy Rapidly Reduced Heparan Sulfate (HS) Exposure in Cerebrospinal Fluid (CSF) and Improved Long-term Cognitive Function in Children with Mucopolysaccharidosis IIIA (MPS IIIA) "
-
Dr. Lau has received personal compensation for serving as an employee of Ultragenyx. Dr. Lau has stock in Ultragenyx.
-
Dr. Patra has received personal compensation for serving as an employee of Ultragenyx. Dr. Patra has stock in Ultragenyx.
-
Mrs. Wolf has received personal compensation for serving as an employee of Ultragenyx Pharmaceutical. Mrs. Wolf has stock in Ultragenyx Pharmaceutical.
-
The institution of Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Forge Bio. The institution of Dr. Smith has received research support from Ultragenyx. The institution of Dr. Smith has received research support from Cyclotherapeutics. The institution of Dr. Smith has received research support from BluebirdBio. The institution of Dr. Smith has received research support from Sanfilippo Children's Foundation. The institution of Dr. Smith has received research support from Medical Research Future Fund. The institution of Dr. Smith has received research support from Women's and Children's Hospital Foundation.
-
Prof. Couce has nothing to disclose.
-
Dr. Rajan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Rajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Rajan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink Neurology. The institution of Dr. Rajan has received research support from National Scleroderma Foundation. The institution of Dr. Rajan has received research support from Denali Therapeutics. The institution of Dr. Rajan has received research support from Ultragenyx . The institution of Dr. Rajan has received research support from Regenxbio. The institution of Dr. Rajan has received research support from Takeda. The institution of Dr. Rajan has received research support from Prevail Therapeutics. The institution of Dr. Rajan has received research support from Children's Neuroscience Institute. Dr. Rajan has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Truxal has received research support from Ultragenyx. The institution of Dr. Truxal has received research support from Inozyme Therapeutics.
-
Dr. Lopez has nothing to disclose.
-
The institution of Prof. Fuller has received research support from Alexion. The institution of Prof. Fuller has received research support from Ultragenyx. The institution of Prof. Fuller has received research support from Sanofi. The institution of Prof. Fuller has received research support from Paradigm.
-
Mrs. Monteagudo has nothing to disclose.
-
Ms. Dougherty has nothing to disclose.
-
Dr. del Toro has nothing to disclose.
-
Dr. Flanigan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apic Bio. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AavantiBio. Dr. Flanigan has stock in 4D Molecular Therapeutics. The institution of Dr. Flanigan has received research support from Abeona Therapeutics. The institution of Dr. Flanigan has received research support from Sarepta Therapeutics. The institution of Dr. Flanigan has received research support from Astellas Therapeutics. Dr. Flanigan has received intellectual property interests from a discovery or technology relating to health care.